|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Takeda_Pharmaceutical_Company
January 2019
Acquired_by_Takeda_in_2018
|
|
gptkbp:advertising
|
gptkb:Dr._Christine_Carr
|
|
gptkbp:CEO
|
gptkb:Christine_Carr
gptkb:Dr._Philip_Vickers
gptkb:Dr._Christine_Carr
|
|
gptkbp:clinicalTrials
|
ongoing
completed
|
|
gptkbp:customerService
|
gptkb:Dr._Christine_Carr
|
|
gptkbp:developer
|
gptkb:Dr._Christine_Carr
|
|
gptkbp:drugInterdiction
|
focuses on central nervous system disorders
focuses on endocrinology
focuses on gastrointestinal disorders
focuses on hematology
focuses on immunology
focuses on metabolic disorders
focuses on neuroscience
focuses on ophthalmology
focuses on rare genetic disorders
specializes in rare diseases
|
|
gptkbp:employees
|
over 23,000 (2017)
|
|
gptkbp:founded
|
1986
|
|
gptkbp:founder
|
gptkb:Harry_Stratford
|
|
gptkbp:headquarters
|
gptkb:Lexington
gptkb:Lexington,_Massachusetts,_USA
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Shire plc
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:market
|
$62 billion (2018)
|
|
gptkbp:operations
|
gptkb:Dr._Philip_Vickers
|
|
gptkbp:partnerships
|
gptkb:AstraZeneca
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Baxter_International
gptkb:Pfizer
|
|
gptkbp:products
|
Adderall
Intuniv
Vyvanse
Gaucher_disease_treatments
|
|
gptkbp:regulates
|
gptkb:Dr._Philip_Vickers
|
|
gptkbp:research
|
gptkb:Dr._Philip_Vickers
|
|
gptkbp:research_areas
|
internal medicine
rare diseases
neuroscience
ophthalmics
|
|
gptkbp:research_focus
|
genetic disorders
central nervous system disorders
gastrointestinal diseases
metabolic diseases
|
|
gptkbp:revenue
|
$15.2 billion (2017)
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
SHPG
|
|
gptkbp:subsidiary
|
gptkb:Shire_International_GmbH
gptkb:Shire_US_Inc.
|
|
gptkbp:supplyChain
|
gptkb:Dr._Philip_Vickers
|